Terms ending in 2037
Every in-force patent on BioAtla Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,822,426 | Humanized ANTI-CD73 Antibodies In force · High confidence | Corvus Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,859,007 | Humanized ANTI-CD73 Antibodies In force · High confidence | Corvus Pharmaceuticals, Inc. | In force | High confidence | |
| US 11,472,876 | Conditionally Active Polypeptides In force · Medium confidence | BioAtla, Inc. | In force | Medium confidence | |
| US 10,697,972 | Diagnostics Using Conditionally Active Antibodies In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 11,149,088 | Anti-Axl Antibodies, Antibody Fragments and Their Immunoconjugates and Uses Thereof In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 11,897,959 | Anti-Axl Antibodies, Antibody Fragments and Their Immunoconjugates and Uses Thereof In force · Medium confidence | BioAtla, Inc. | In force | Medium confidence | |
| US 11,279,924 | Conditionally Active Polypeptides and Methods of Generating Them In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 11,254,742 | ANTI-ROR2 Antibodies, Antibody Fragments, Their Immunoconjucates and Uses Thereof In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 12,186,278 | Mesothelin Chimeric Antigen Receptor (CAR) and Antibody Against PD-L1 Inhibitor for Combined Use in Anticancer Therapy In force · High confidence | Novartis AG and The Trustees of the University of Pennsylvania | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by BioAtla Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.